Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells

Autor: Heba M. Zahid, Kristy A. Brown, Maria M. Docanto, Richard L. Ferrero, John B. Furness, CheukMan C Au, Francesca Maria Raffaelli

Publikováno v: The Journal of Steroid Biochemistry and Molecular Biology. 170:49-53

Des-acyl ghrelin is the unacylated form of the well-characterized appetite-stimulating hormone ghrelin. It affects a number of physiological processes, including increasing adipose lipid accumulation and inhibiting adipose tissue inflammation. Breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462dddd2f9bbd6c9dec69916aa650198
https://doi.org/10.1016/j.jsbmb.2016.07.005

Timeless Is a Novel Estrogen Receptor Co-activator Involved in Multiple Signaling Pathways in MCF-7 Cells

Autor: Morag J. Young, Chantal Beatrice Magne Nde, Colin Clyne, Jakob Buehn, Kevin Christopher Knower, Gloria Casas Gimeno, Edris Sayed, Maria M. Docanto

Publikováno v: Journal of molecular biology. 430(10)

Activation of estrogen receptor α (ERα) stimulates cell division and tumor growth by modulating the expression of ERα target genes. This activation involves the recruitment of specific proteins with activities that are still not fully understood.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4811f4fb27623daa417f4883bbdd3d57
https://pubmed.ncbi.nlm.nih.gov/29555554

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.

Autor: Fettke H; Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: Heidi.fettke@petermac.org., Dai C; Predicine Inc., Hayward, CA, USA., Kwan EM; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia., Zheng T; Predicine Inc., Hayward, CA, USA., Du P; Predicine Inc., Hayward, CA, USA., Ng N; Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Bukczynska P; Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Docanto M; Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Kostos L; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Foroughi S; Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, Australia; Personalized Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Brown S; Medical Oncology, Ballarat Base Hospital, Ballarat, Australia., Graham LK; Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia., Mahon K; Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia; University of Sydney, Sydney, Australia; Garvan Institute of Medical Research, Darlinghurst, Australia., Horvath LG; Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia; University of Sydney, Sydney, Australia; Garvan Institute of Medical Research, Darlinghurst, Australia; Royal Prince Alfred Hospital, Camperdown, Australia., Jia S; Predicine Inc., Hayward, CA, USA., Kohli M; Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Azad AA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Publikováno v: EBioMedicine [EBioMedicine] 2023 Sep; Vol. 95, pp. 104738. Date of Electronic Publication: 2023 Aug 05.

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.

Autor: Lin HM; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia.; St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia., Huynh K; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Kohli M; Division of Oncology, Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA., Tan W; Mayo Clinic Florida, Jacksonville, FL, USA., Azad AA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Monash University, Melbourne, VIC, Australia., Yeung N; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia., Mahon KL; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia.; Monash University, Melbourne, VIC, Australia.; Chris O' Brien Lifehouse, Camperdown, NSW, Australia.; University of Sydney, Sydney, NSW, Australia., Mak B; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia.; Chris O' Brien Lifehouse, Camperdown, NSW, Australia.; University of Sydney, Sydney, NSW, Australia., Sutherland PD; Royal Adelaide Hospital, Adelaide, SA, Australia., Shepherd A; Royal Adelaide Hospital, Adelaide, SA, Australia.; Adelaide Medical School and Freemason's Foundation Centre for Men's Health, University of Adelaide, Adelaide, SA, Australia., Mellett N; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Docanto M; Monash University, Melbourne, VIC, Australia., Giles C; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Centenera MM; Adelaide Medical School and Freemason's Foundation Centre for Men's Health, University of Adelaide, Adelaide, SA, Australia.; South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Butler LM; Adelaide Medical School and Freemason's Foundation Centre for Men's Health, University of Adelaide, Adelaide, SA, Australia.; South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Meikle PJ; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Horvath LG; Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia. lisa.horvath@lh.org.au.; St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia. lisa.horvath@lh.org.au.; Chris O' Brien Lifehouse, Camperdown, NSW, Australia. lisa.horvath@lh.org.au.; University of Sydney, Sydney, NSW, Australia. lisa.horvath@lh.org.au.; Royal Prince Alfred Hospital, Camperdown, NSW, Australia. lisa.horvath@lh.org.au.

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2021 Sep; Vol. 24 (3), pp. 860-870. Date of Electronic Publication: 2021 Mar 21.

Timeless Is a Novel Estrogen Receptor Co-activator Involved in Multiple Signaling Pathways in MCF-7 Cells.

Autor: Magne Nde CB; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia. Electronic address: chantal.nde@hudson.org.au., Casas Gimeno G; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia., Docanto M; Monash University, Clayton, Victoria 3168, Australia., Knower KC; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia., Young MJ; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia; Monash University, Clayton, Victoria 3168, Australia., Buehn J; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia., Sayed E; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia., Clyne CD; Cancer Drugs Discovery, Centre of Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia; Monash University, Clayton, Victoria 3168, Australia.

Publikováno v: Journal of molecular biology [J Mol Biol] 2018 May 11; Vol. 430 (10), pp. 1531-1543. Date of Electronic Publication: 2018 Mar 16.